Cytospire Therapeutics

News

Cytospire was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of T-cell engager (TCE) for cancer.

Oncology

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.